(Reuters) - Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals ...

The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...

Alexion's plan to switch patients from blockbuster Soliris to newcomer Ultomiris in on track. But why isn't the company's share price reflecting that? (Alexion) In its push to backstop sales of ...

The FDA granted Alexion Pharmaceuticals’ (ALXN) Soliris orphan drug designation for treating patients suffering from myasthenia gravis (MG), a rare autoimmune deficiency which leads to the failure of ...

FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis · GlobeNewswire Inc. New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes ...

Alexion's rare disease drug Soliris is generating blockbuster-level sales – but the US biotech is rushing through development of a successor amid potential competition and US patent expiry in around ...

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143). Treatment with Soliris (eculizumab; Alexion) was associated ...

It took longer than some industry watchers expected, but Alexion has another indication for lead med Soliris in the bag. On Monday, the company said the FDA had greenlighted the product to treat ...

Alexion’s rare disease drug Soliris has been approved in a new use in Europe, to tackle a disorder of the optic nerves for which it recently got FDA approval. The European Commission granted a ...

- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - “We are pleased that the Japanese health ...

(RTTNews) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...